Investor Overview

Corporate Profile

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-100 is an oral alpha-4-beta-7 integrin antagonist peptide  that was being developed for inflammatory bowel diseases (IBD). ... Read more

Stock Quote

PTGX (Common Stock)
$6.25 - 0.09 (1.42%)
Exchange :NASDAQ
Volume :72,811
Today's Open$6.32
Previous Close$6.34
Data as of May 22, 2018 11:37 a.m. ET
Refresh quote

Stock Chart

Stock chart for: PTGX.O.  Currently trading at $6.25 with a 52 week high of $23.97 and a 52 week low of $5.50.

Recent Press Releases

May 17, 2018

Protagonist Therapeutics Announces Two Oral Presentations Accepted for 23rd Congress of the European Hematology Association read more

May 16, 2018

Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors read more

May 09, 2018

Protagonist Therapeutics Reports First Quarter 2018 Financial Results read more

Upcoming Events

Presentation

Download Documentation Investor Presentation
Data provided by Nasdaq. Minimum 15 minutes delayed.